Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.